Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

160
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
160
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.8K
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod.

Clinical and translational science·2026
Same author

In Vivo Base Editing of <i>PCSK9</i> with VERVE-102 for Hypercholesterolemia.

The New England journal of medicine·2026
Same author

Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group Study.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2025
Same author

Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.

The New England journal of medicine·2025
Same author

Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus.

The British journal of dermatology·2025
Same author

Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis.

Journal of hepatology·2025

Related Experiment Video

Updated: Dec 29, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.4K

Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs.

Simon Coates1, Oliver Pohl2, Jean-Pierre Gotteland2

  • 1Richmond Pharmacology Ltd, St Georges University of London, SW17 0RE, London, United Kingdom. s.coates@richmondpharmacology.com.

Therapeutic Innovation & Regulatory Science
|February 3, 2020
PubMed
Summary

Adaptive trial designs accelerate drug development by reducing timelines and costs. This study demonstrates an efficient, 11-month program for a preterm labor drug using integrated adaptive protocols with few participants.

Keywords:
adaptive designearly-phase clinical researchprotocol writing

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.0K

Related Experiment Videos

Last Updated: Dec 29, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.4K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.0K

Area of Science:

  • Clinical Pharmacology
  • Drug Development
  • Regulatory Science

Background:

  • Adaptive trial designs offer flexibility and efficiency in drug development, reducing timelines and costs.
  • Implementing adaptive strategies can introduce complexity in protocol design and execution.
  • Previous work established a methodology for writing early-phase adaptive integrated protocols.

Purpose of the Study:

  • To demonstrate the practical implementation of an adaptive protocol writing methodology for early drug development.
  • To describe the integration of two interdependent, adaptive trial protocols for a novel drug, OBE022.
  • To highlight the challenges and efficiencies encountered during the adaptive trial program.

Main Methods:

  • Utilized two interdependent, adaptive trial protocols for the early development program of OBE022, a prostaglandin F2a receptor antagonist for preterm labor.
  • Integrated first-in-human single and multiple ascending dose studies, including assessments of food effect, cardiac safety, proof of concept, and drug interactions.
  • Leveraged the UK's regulatory environment accepting rules-guided progression for seamless protocol amendments.

Main Results:

  • The adaptive trials were tailored to OBE022's pharmacokinetic/pharmacodynamic properties and therapeutic indication.
  • Predefined adaptive options allowed for protocol changes as non-substantial amendments, maintaining timelines.
  • The program successfully achieved its objectives, completing in 11 months with only 83 participants.

Conclusions:

  • The integrated adaptive protocol approach efficiently covered key early drug development elements: dose-ranging, safety, and proof of concept.
  • This methodology demonstrates a time- and cost-efficient strategy for designing, executing, analyzing, and reporting early-phase drug development programs.
  • Adaptive trial designs, when practically implemented, significantly enhance the efficiency of early drug development.